The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Cipla has reported consolidated financial results for the period ended September 30, 2021
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
Support from DFC will help produce one billion vaccine doses by the end of 2022
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
The division is expected to grow to over a 100-member strong team by 2022
Subscribe To Our Newsletter & Stay Updated
